Call your doctor before leaving home if you think you’ve been exposed to COVID-19 or have symptoms

Due to the presence of COVID-19 in our community, visitor restrictions are in place for all Duke clinics and hospitals. For your safety and the safety of others, we recommend patients do not bring a visitor to Duke clinics, if at all possible. If a visitor must accompany a patient, only one individual over 12 years of age is allowed. Patients and visitors will be screened for symptoms upon arrival. Individuals with flu-like symptoms are not allowed. View the complete list of Visitor Restrictions.

Effective immediately, Duke Health is prioritizing and rescheduling some non-emergent or non-critical surgeries, procedures, and appointments. Check our COVID-19 (Coronavirus) page for updates.

Array-818-202 for Non-small Cell Lung Cancer - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn about the safety and effectiveness of the study drugs (Encorafenib and Binimetinib) in patients.
What is the Condition Being Studied?
Non-Small Cell Lung Cancer (NSCLC)

Who Can Participate in the Study?

Adults 19 years or older with NSCLC with a gene called BRAFV600E that has mutated.

Age Group

What is Involved?

If you choose to join this study, you will:
-Be in the study up to 2 years
-Take study drugs daily
-Give blood samples
-Possible give a small lung tissue sample
-Continue with your regular care

Study Details

Full Title
PHAROS: A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAF-V600E-mutant Non-small Cell Lung Cancer
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00102193
NCT: NCT03915951
Phase II
Contact the Duke Recruitment Innovation Center